Kymera Therapeutics, Inc. (KYMR)

USD 39.06

(-7.66%)

Market Cap (In USD)

2.52 Billion

Revenue (In USD)

78.59 Million

Net Income (In USD)

-146.96 Million

Avg. Volume

565.62 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
22.35-53.27
PE
-
EPS
-
Beta Value
2.219
ISIN
US5015751044
CUSIP
501575104
CIK
1815442
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Nello Mainolfi M.D., Ph.D.
Employee Count
-
Website
https://www.kymeratx.com
Ipo Date
2020-08-21
Details
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.